FDA Approves Larotrectinib for NTRK-Positive Solid Tumors
The FDA has granted full approval to larotrectinib for select patients with solid tumors harboring a NTRK gene fusion.
Related Articles
FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has awarded full approval to frontline nivolumab plus ipilimumab for the treatment of adult patients with unresectable hepatocellular carcinoma.
PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.
Dr Kuerer on Selective Surgery Omission After Response to Neoadjuvant Therapy in Invasive Breast Cancer
Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses a study on selective elimination of breast surgery after exceptional response to neoadjuvant therapy in early breast…
CEPHEUS Data Support D-VRd in Transplant-Ineligible or -Deferred Patients With Myeloma Who Can Tolerate Bortezomib
D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.
OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025
Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.
Clinical Approaches in Treating HER2+ Breast Cancer and Brain Metastases
Panelists discuss how they approach the treatment of HER2-positive advanced breast cancer with brain metastases, outlining the criteria for therapy selection, the role of patient-specific…
Dr Moschos on Treatment Strategies With Adoptive T-Cell Therapy in Melanoma
Stergios J. Moschos, MD, discusses how the use of bridging therapy can enhance the efficacy of adoptive T-cell therapies for patients with melanoma.
Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC
Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.
Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration
Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.
Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX
The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.